Pityriasis versicolor: an update on pharmacological treatment options
Introduction: Pityriasis versicolor (PV) is a superficial fungal infection caused by Malassezia species; a yeast that naturally colonizes on the skins surface. High efficacy rates are generally obtained with both topical and systemic treatments. However, recurrence rates following successful treatment remain high and there are no dosage guidelines available for administration of systemic antifungal agents that carry risks of adverse events.
Expert Option 帳戶類型 Areas covered: This review focused on providing an overview of existing treatments for Expert Option 帳戶類型 PV and an introduction to new treatments. A literature search was conducted using the search strategy, pityriasis versicolor OR tinea versicolor. Over the past decade, few new treatments have been introduced, but the efficacy and the dosing regimens of existing treatments have been systematically reviewed. The results of these reviews are discussed.
Expert opinion: Existing topical Expert Option 帳戶類型 Expert Option 帳戶類型 and systemic agents are both effective treatments against PV. Previous dosage recommendations for systemic agents have been modified based on recent evidence elucidated in systematic reviews. However, the absence of standardized collection and reporting practices in clinical trials precludes any conclusions to be drawn regarding the efficacy and safety of topical and systemic agents in comparison or in concert with each other.
Keywords: pityriasis versicolor; systemic antifungal; tinea versicolor; topical antifungal; treatment.
Gupta AK, Kogan N, Batra R. Gupta AK, et al. Expert Expert Option 帳戶類型 Opin Pharmacother. 2005 Feb;6(2):165-78. doi: 10.1517/146565220.127.116.11. Expert Opin Pharmacother. 2005. PMID: 15757415 Review.
Sharma A, Rabha D, Ahmed G. Sharma A, et Expert Option 帳戶類型 al. Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):249-251. doi: 10.4103/0378-6323.193617. Indian J Dermatol Venereol Leprol. 2017. PMID: 27852993 No abstract available.
Kallini JR, Riaz Expert Option 帳戶類型 F, Khachemoune A. Kallini JR, et al. Int J Dermatol. 2014 Feb;53(2):137-41. doi: 10.1111/ijd.12345. Epub 2013 Dec 10. Int J Dermatol. 2014. PMID: 24320140 Review.
Gupta AK, Bluhm R, Summerbell R. Gupta AK, et al. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. doi: 10.1046/j.1468-3083.2002.00378.x. J Expert Option 帳戶類型 Eur Acad Dermatol Venereol. 2002. PMID: 11952286 Review.
Cantrell WC, Elewksi BE. Cantrell WC, Expert Option 帳戶類型 et al. J Drugs Dermatol. 2014 Jul;13(7):855-9. J Drugs Dermatol. 2014. PMID: 25007370 Clinical Trial.
Hobi S, Cafarchia C, Romano V, Barrs VR. Hobi S, et al. J Fungi (Basel). 2022 Jul 4;8(7):708. doi: 10.3390/jof8070708. J Fungi (Basel). 2022. PMID: 35887463 Free PMC article. Review.
Georgescu SR, Mitran CI, Mitran MI, Matei C, Popa GL, Erel O, Tampa M. Georgescu SR, et al. J Clin Med. 2022 Mar 9;11(6):1507. doi: 10.3390/jcm11061507. J Clin Med. 2022. PMID: 35329832 Free PMC article. Review.
Expert Systems with Applications
Expert Systems With Applications is a refereed international journal whose focus is on exchanging information relating to expert and intelligent systems applied in industry, government, and universities worldwide. The thrust of the journal is to publish papers dealing with the design, development, testing, implementation, and/or management of expert and intelligent systems, and also to provide practical guidelines in the development and management of these systems. The journal will publish papers in expert and intelligent systems technology and application in the areas of, but not limited to: finance, accounting, engineering, marketing, auditing, Expert Option 帳戶類型 law, procurement and contracting, project management, risk assessment, information management, information retrieval, crisis management, Expert Option 帳戶類型 stock trading, strategic management, network management, telecommunications, space education, intelligent front ends, intelligent database management systems, medicine, chemistry, human resources management, human capital, business, production management, archaeology, economics, energy, and defense. Papers in multi-agent systems, knowledge management, neural networks, knowledge discovery, data and text mining, multimedia mining, and genetic algorithms will also be published in the journal.
Reproducibility Expert Option 帳戶類型 Badge Initiative and Software Publication
Reproducibility Badge Initiative (RBI) is a collaboration with Code Ocean (Expert Option 帳戶類型 CO), a cloud based computational reproducibility platform that helps the community by enabling sharing of Expert Option 帳戶類型 code and data as a resource for non-commercial use. CO verifies the submitted code (Expert Option 帳戶類型 and data) and certifies its reproducibility. Code submission will be verified by the Code Expert Option 帳戶類型 Ocean team for computational reproducibility by making sure it runs, delivers results and it is self-contained. For more information please visit this help article . Note that an accepted paper will be published independently of the CO application outcome. However, if the paper receives the Reproducibility badge, it will be given additional exposure by having an attached R Badge, and by being citable at the CO website with a DOI.
We invite you to convert your open source software into an additional journal publication in Software Impacts , a multi-disciplinary open access journal. Software Impacts provides a scholarly reference to software that has been used to address a research challenge. The journal disseminates impactful Expert Option 帳戶類型 and re-usable scientific software through Original Software Publications which describe the application of the software to research and the published outputs.
For more information contact us at: [email protected]
Benefits to authors
We also provide many author benefits, such as free PDFs, a Expert Option 帳戶類型 liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .
Please see our Guide for Authors for information Expert Option 帳戶類型 on article submission. If you require any further information or help, please visit our Support Center
Expert Option 帳戶類型
Sign up for our bi-monthly newsletter with frequently asked questions about design of experiments.
© Stat-Ease, Inc. 2022. Design-Expert® Software is a registered trademark of Stat-Ease, Inc.
Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee
In 2017, a National Rosacea Society Expert Committee developed and published an updated classification of Expert Option 帳戶類型 rosacea to reflect current insights into rosacea pathogenesis, pathophysiology, and management. These developments suggest that a multivariate disease process underlies the various clinical manifestations of the disorder. The new system is consequently based on phenotypes that link to this process, providing clear parameters for research and diagnosis as well as encouraging clinicians to assess and treat the disorder Expert Option 帳戶類型 as it may occur in each individual. Meanwhile, a range of therapies has become available for rosacea, and their roles have been increasingly defined in clinical practice as Expert Option 帳戶類型 Expert Option 帳戶類型 the disorder has become more widely recognized. This update is intended to provide a comprehensive Expert Option 帳戶類型 summary of management options, including expert evaluations, to serve as a guide for tailoring treatment and care on an individual basis to achieve optimal patient outcomes.
Keywords: drugs; erythema; flushing; lasers; lifestyle; management; ocular; papules; phenotypes; phymatous; pustules; rosacea; telangiectasia; therapy; utility.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Gallo RL, et al. J Am Acad Dermatol. 2018 Jan;78(1):Expert Option 帳戶類型 148-155. doi: 10.1016/j.jaad.2017.08.037. Epub 2017 Oct 28. J Am Acad Dermatol. 2018. PMID: 29089180 Review.
Buechner SA. Buechner SA. Dermatology. 2005;210(2):100-8. doi: 10.1159/000082564. Dermatology. 2005. PMID: 15724091 Review.
Kang CN, Shah M, Tan J. Kang CN, et al. Skin Therapy Lett. 2021 Jul;26(4):1-8. Skin Therapy Lett. 2021. PMID: 34347259
Oge' LK, Muncie HL, Phillips-Savoy AR. Oge' LK, et al. Am Fam Physician. 2015 Aug 1;92(3):187-96. Am Fam Physician. 2015. PMID: 26280139
Elsaie ML, Choudhary Expert Option 帳戶類型 S. Elsaie ML, et al. Postgrad Med. 2009 Sep;121(5):178-86. doi: 10.3810/pgm.2009.09.2066. Postgrad Med. 2009. PMID: 19820288 Review.
Wang H, An X, Wang Z. Wang H, et al. Evid Based Complement Alternat Med. 2022 Jul 12;2022:3335074. doi: 10.1155/2022/3335074. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35865346 Free PMC article.
Maliyar K, Abdulla SJ. Maliyar K, et al. Drugs Context. 2022 May 31;11:2021-11-1. doi: 10.7573/dic.2021-11-1. eCollection 2022. Drugs Context. 2022. PMID: 35720055 Free PMC article. Review.
Zhang H, Zhang Y, Li Y, Wang Y, Yan S, Xu S, Deng Z, Yang X, Xie H, Li J. Zhang H, et al. Front Immunol. 2021 Nov 23;12:756550. doi: 10.3389/fimmu.2021.756550. eCollection 2021. Front Immunol. 2021. PMID: 34899707 Free PMC article.
Miyachi Y, Yamasaki K, Fujita T, Fujii C. Miyachi Y, et al. J Dermatol. 2022 Mar;49(3):330-340. doi: 10.1111/1346-8138.16254. Epub 2021 Dec 1. J Dermatol. 2022. PMID: 34854112 Free PMC article. Clinical Trial.
Del Rosso JQ, Webster G, Weiss JS, Bhatia ND, Gold LS, Kircik L. Del Expert Option 帳戶類型 Rosso JQ, et al. J Clin Aesthet Dermatol. 2021 Aug;14(8):14-21. Epub 2021 Aug 1. J Clin Aesthet Dermatol. 2021. PMID: 34840653 Free PMC article. Review.